Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

Completed · Early Phase 1

Conditions studied: Chronic Myeloproliferative Disorders, Leukemia

In brief

RATIONALE: Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the abnormal cells. PURPOSE: This clinical trial is studying the side effects and how well bortezomib works in treating patients with advanced myeloproliferative disorders.

Key facts

Study ID

NCT00437086

Run by

Mayo Clinic

People needed

30

Starts

2005-09-01

Expected to finish

2008-11-01

Last updated by the study team

2014-10-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Mayo Clinic in Florida — Jacksonville, Florida, United States
• Mayo Clinic — Rochester, Minnesota, United States
• M. D. Anderson Cancer Center at University of Texas — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.